British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

Biomedicines, published by MDPI, is a prestigious open-access journal dedicated to the rapidly evolving fields of biochemistry, genetics, and molecular biology, as well as broader aspects of medicine. Since its inception in 2013, Biomedicines has established itself as a leading platform for researchers, practitioners, and students to disseminate high-quality research and innovative findings, reflected in its impressive Q1 ranking in both the Biochemistry, Genetics and Molecular Biology and Medicine categories. With its commitment to accessibility and impactful scholarship, the journal has quickly garnered an international readership, positioning itself as a vital resource in advancing scientific knowledge and fostering collaboration in the biomedical community. Operating from its headquarters in Basel, Switzerland, Biomedicines continues to thrive with features such as rigorous peer review and a fast publication process, making it an essential journal for those looking to contribute to and stay updated in their respective fields.

The Journal of Clinical and Translational Science, published by Cambridge University Press, stands at the forefront of advancing the fields of clinical and translational medicine. With an impressive impact factor denoting its significance within the scientific community, this peer-reviewed, Open Access journal, which has embraced open dissemination of research since 2017, provides a crucial platform for researchers, professionals, and students dedicated to exploring innovative methodologies and translating scientific discoveries into practical applications. Situated in the United Kingdom, the journal reflects a commitment to fostering collaboration and knowledge exchange among scholars, as evidenced by its respectable Q2 ranking in the Medicine (miscellaneous) category and a robust position in Scopus rankings (192 out of 636) with a 69th percentile. Covering a wide scope within clinical and translational domains, it aims to rapidly publish high-quality research, thereby accelerating the translation of laboratory findings into clinical practice. By bridging gaps between disparate research areas, the Journal of Clinical and Translational Science plays a pivotal role in driving medical innovation and improving healthcare outcomes globally.

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

Current Medical Science is a prominent academic journal dedicated to advancing knowledge in the fields of Medicine, Biochemistry, and Genetics. Published by SPRINGER with an ISSN of 2096-5230 and E-ISSN 2523-899X, this journal is based in China and serves as a vital resource for researchers, professionals, and students alike. With a focus on innovative research and emerging trends, Current Medical Science has established itself with an impactful presence, operating under Open Access guidelines to ensure wide dissemination of scientific findings. The journal's recognition is underscored by its impressive Scopus rankings, including a Q3 quartile placement in Biochemistry and Genetics as of 2023. It is noteworthy that the journal spans converged years from 2018 to 2024, providing a comprehensive platform for scholarly discussions and developments that drive the evolution of medical science. As it continues to publish influential research, Current Medical Science plays an essential role in bridging the gap between laboratory science and clinical application.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

PHARMACEUTICAL STATISTICS is a premier academic journal published by Wiley, focusing on the intersection of pharmacology and statistics. With the ISSN 1539-1604 and E-ISSN 1539-1612, this journal has established itself as a leading resource in the field since its inception in 2004, with a targeted convergence year extending to 2024. Notably, it ranks in the Q1 category for both pharmacology and statistics, reflecting its high impact and significance within these disciplines. The journal embraces a wide scope, encompassing statistical methodology and its application in pharmaceuticals, thus serving as an essential platform for researchers, professionals, and students committed to advancing their knowledge and practice. Its notable placement in Scopus rankings further reinforces its academic credibility, making it a valuable reference point for high-quality research. Although this journal does not currently offer open access options, it remains a vital source of insights and research advancements in the pharmaceutical sciences.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Expert Opinion on Therapeutic Targets, published by Taylor & Francis Ltd, is a highly respected journal in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With a focus on cutting-edge research and innovative approaches to therapeutic development, this journal has established itself as a leading platform for scholars and practitioners, boasting a prestigious Q1 ranking across multiple categories in 2023. The journal aims to present expert perspectives on novel therapeutic strategies, promising drug candidates, and insights into the intricate mechanisms underlying various diseases. Its impressive impact factor reflects the journal's commitment to advancing scientific knowledge and influencing clinical practice. With its inception in 1997 and ongoing publication through to 2024, Expert Opinion on Therapeutic Targets continues to be an invaluable resource for those seeking to stay at the forefront of therapeutic innovations.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.